• Own Lindus Health's approach to clinical trial monitoring across our portfolio. Design and oversee risk-based, proportional monitoring strategies for each trial, determining what to monitor, how frequently, and with what intensity. Challenge traditional monitoring assumptions and ensure we're consistently applying the right level of oversight to protect patients and data integrity without unnecessary burden. • Provide line management and coaching to our CRA team, building their capability to think critically about monitoring rather than simply following scripts. Set clear expectations, ensure accountability and follow-through after monitoring visits, and develop less experienced CRAs on best practices, proportionality, and taking initiative. • Conduct on-site and remote monitoring visits as needed to support the team during peak periods, cover complex or high-risk trials, or model best practices for the CRA team. Maintain your clinical monitoring skills and stay connected to the practical realities of site-level work. • Represent monitoring strategy in bid meetings and sponsor conversations. Confidently propose and defend creative, risk-based monitoring approaches, explaining why Lindus monitors differently and how our approach benefits trial quality and efficiency. Build sponsor trust in our monitoring capabilities. • Act as the monitoring voice into our product and technology teams, particularly for our Citrus platform. Translate monitoring requirements into clear, lay-term product needs, drawing on your experience with other EDC and monitoring systems. Ensure our technology supports compliant, efficient monitoring workflows and identify opportunities for innovation. • Work collaboratively with UK/EU Clinical Operations teams to develop and maintain consistent monitoring standards and processes across regions, while allowing for appropriate local flexibility. • Spot patterns across trials, identify areas for improvement in our monitoring approach, and drive implementation of new processes or tools. Stay current on regulatory expectations and industry best practices in risk-based monitoring.